Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and… (NCT06234514) | Clinical Trial Compass
CompletedPhase 4
Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab
China111 participantsStarted 2023-01-01
Plain-language summary
The objective of this study was to investigate the efficacy and safety of traditional Chinese medicine (Jueling Mingmu Decoction) combined with ranibizumab in the treatment of macular edema with retinal vein obstructive.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Foveal center-involved macular edema (ME) lasting less than 9 months
* Central Macular Thickness (CMT) greater than or equal to 250 ÎĽm
* Best-Corrected Visual Acuity (BCVA) of 24-73 letters (20/40 to 20/320) in the study eye
* Initial diagnosis with no prior treatments, such as laser therapy or intravitreal injections
Exclusion Criteria:
* Presence of any additional macular pathology, such as age-related macular degeneration (AMD) or diabetic retinopathy (DR) affecting the macula
* Concurrent serious conditions, such as cardiovascular diseases, liver, or kidney diseases
* Concerns or doubts regarding treatment
* Known allergies to the ingredients of the medication.